With 56% institutional ownership, Altimmune, Inc. (NASDAQ:ALT) is a favorite amongst the big guns [Yahoo! Finance]
Altimmune, Inc. (ALT)
NASDAQ:AMEX Investor Relations:
altimmune.com/investors
Company Research
Source: Yahoo! Finance
A total of 25 investors have a majority stake in the company with 47% ownership Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company To get a sense of who is truly in control of Altimmune, Inc. ( NASDAQ:ALT ), it is important to understand the ownership structure of the business. With 56% stake, institutions possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company. Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait. In the chart below, we zoom in on the different ownership groups of Altimmune. View our latest analysis for Altimmune Institutional investors commonly compare their own returns to the re
Show less
Read more
Impact Snapshot
Event Time:
ALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALT alerts
High impacting Altimmune, Inc. news events
Weekly update
A roundup of the hottest topics
ALT
News
- Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial [Yahoo! Finance]Yahoo! Finance
- Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH TrialGlobeNewswire
- Altimmune announces CEO transition [Seeking Alpha]Seeking Alpha
- Altimmune Announces CEO Transition and Succession PlanGlobeNewswire
- Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
ALT
Earnings
- 11/6/25 - Beat
ALT
Sec Filings
- 12/19/25 - Form 8-K
- 12/8/25 - Form EFFECT
- 12/1/25 - Form 4
- ALT's page on the SEC website